Transgenomic Posts Slight Rise in Q2 Revenues, Modest Profit | GenomeWeb
NEW YORK (GenomeWeb News) — Transgenomic yesterday said first-quarter revenues inched up 1.5 percent as R&D spending increased 7 percent and the company turned last year’s loss to a modest profit.     
 
Total receipts for the three months ended June 31 rose to $6.3 million from $6.2 million year over year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.